VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ELCC 2019 | Phase III real-world PACIFIC-R trial for NSCLC

Nicolas Girard, MD, PhD, from Claude Bernard University, Lyon, France, gives an overview of the real-world Phase III PACIFIC-R trial (NCT03798535), where post-chemoradiotherapy administration of durvalumab shows promising results in patients with unresectable stage III non-small cell lung cancer (NSCLC). At the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Girard then discusses the strategies for clinical trial expansion.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter